Momentum Group Limited Overview
Momentum Group is one of South Africa's largest diversified insurance and financial services groups. It earns profits across life insurance, investment and savings platforms, employee benefits, specialist non-life insurance, and healthcare administration. Its multi-brand model separates the affluent-market Momentum franchise from the mass-market Metropolitan brand, and adds Guardrisk, South Africa's leading cell-captive and alternative-risk-transfer insurer. Momentum Health is now the country's second-largest medical scheme administrator after taking over Bonitas Medical Fund in June 2026. Outside South Africa, the group has a shrinking but more profitable African footprint (Namibia, Botswana, Lesotho), a UK investment manager (MGIM), and a 44.1% stake in India's Aditya Birla Health Insurance. Under CEO Jeanette Marais's Impact strategy (FY2025–FY2027), the group delivered record normalised headline earnings of R7.06bn and a 21.7% ROE in FY2026, a year early. Value of new business remains the main gap against its own targets.
What the company does
Momentum Group sells and administers financial protection, savings, retirement and investment products, and healthcare administration services, to individuals, employers, retirement funds, medical schemes and corporate risk owners. Earnings come from three broad sources:
-
Life insurance margins. These are the release of the IFRS 17 contractual service margin (CSM), risk adjustment release, and experience variances (mortality, morbidity, persistency, expenses) on protection, annuity and savings business written by Momentum Retail, Metropolitan Life, Momentum Corporate, Momentum Investments (annuities) and Momentum Africa. The group CSM was R20.4bn at 30 June 2025 and R20.99bn at 31 March 2026 (FY2025 results SENS; Q3 FY2026 operating update).
-
Fee and platform income. This is asset-based fees on the Momentum Wealth platforms, asset management and multi-management (Momentum Investments, MGIM), administration and managed-care fees (Momentum Health), cell-captive management fees (Guardrisk), and umbrella fund administration (Momentum Corporate's FundsAtWork). Momentum Investments reported assets under administration of R581bn and assets under management of R611.5bn at end-FY2026 (FY2026 results as reported by Moonstone, 21 September 2026).
-
Non-life underwriting results. These come from Momentum Insure (personal and commercial short-term insurance) and Guardrisk General Insurance and Guardrisk Life (underwriting on the group's own balance sheet plus cell-captive arrangements).
Shareholders also earn an investment return on shareholder capital: R779m in FY2025 and about R1.09bn in FY2026 (FY2025 SENS; FY2026 results per Moonstone).
Company's own description
The company describes itself as one of South Africa's largest diversified financial services groups. It offers protection (life and non-life), investment, long-term savings and healthcare administration through its client-facing brands Momentum, Metropolitan and Guardrisk, with Eris as its property brand (paraphrased from Profile's Stock Exchange Handbook entry and company materials). It names financial advice as its key differentiator, and uses technology to support advisers while keeping a human touch (FY2025 results outlook statement, paraphrased).
Independent characterisation
| Revenue model component | Description | Indicative share of FY2026 NHE (derived) |
|---|---|---|
| Life insurance margins (recurring-premium protection, annuities, group risk) | Momentum Retail, Metropolitan Life, Momentum Corporate, annuity book in Momentum Investments, Momentum Africa | Majority (Retail + Metropolitan + Corporate + Africa ≈ 56% of NHE) |
| Platform and asset-management fees | Momentum Wealth, MGIM, multi-management, collective investments | Embedded in Momentum Investments (16.9% of NHE, together with annuities) |
| Administration fees (healthcare and retirement) | Momentum Health (GEMS, Bonitas, Momentum Medical Scheme), FundsAtWork administration | Momentum Health 5.2% plus part of Corporate |
| Non-life underwriting and cell-captive fees | Guardrisk, Momentum Insure | ≈ 21% (Guardrisk 14.7% + Insure 6.7%) |
| Associate earnings | Aditya Birla Health Insurance (44.1%) | 0.3% (first profit in FY2026) |
On revenue model, Momentum is overwhelmingly a service and risk-carrying business. There is no product manufacturing in the industrial sense, no material licensing revenue, and only quasi-subscription income (recurring premiums and medical scheme administration fees). A practical revenue-model split, inferred from FY2025–FY2026 NHE composition and not a company disclosure, is:
On value chain position, Momentum is vertically integrated from product manufacture (underwriting) through distribution and administration. It has tied advice channels (Momentum Financial Planning, the Metropolitan agency force), an IFA-support network (Consult by Momentum), a broker distribution arm (Momentum Distribution Services), and in-house administration. The FY2026 interim results noted that Momentum Financial Planning's vertical integration produced nine times higher net flows into Momentum solutions, rising to R1.2bn, and that Consult's assets under administration grew 25% to R59bn (IOL Business Report, 19 March 2026).
On customer types, the group serves:
-
Affluent and middle-income individuals (Momentum brand).
-
Lower- and middle-income households (Metropolitan brand: funeral, protection, savings).
-
Employers and retirement funds (Momentum Corporate).
-
Medical schemes and their members (Momentum Health: GEMS, Bonitas, Momentum Medical Scheme; about 4m health beneficiaries per the MML debt investor roadshow 2026).
-
Corporates, affinity partners, retailers and banks (Guardrisk cell captives).
-
Policyholders in Namibia, Botswana and Lesotho, and Indian retail health insurance customers through ABHI.
End-markets are South African long-term insurance, retirement and savings, asset management, short-term insurance, healthcare administration and managed care, sub-Saharan African insurance, Indian health insurance, and UK multi-asset investment management.
Strategy
Stated strategy: Impact strategy (F2025–F2027)
The Impact strategy, launched in 2024, aims to position Momentum as a leading South African insurer. It rests on enablers labelled People, Transformation, Digital, Sustainability and Capital deployment (company Impact strategy materials). The main themes, paraphrased from company results statements and investor presentations, are:
-
Advice as differentiator. Deepen client relationships through financial adviser channels, with technology supporting advisers while keeping a human touch.
-
Accountable business units. Units are empowered and measured on output and impact, and each targets profitable growth.
-
Profitable growth and VNB focus. Grow sales volumes and market share in profitable products. VNB is explicitly named the "main area of concern".
-
Efficiency. A group-wide performance-optimisation programme (R810m annualised savings by end-FY2026), policy administration system consolidation, and AI and automation.
-
Disciplined capital deployment. Allocate capital only where returns justify it, pursue value-adding bolt-on acquisitions, and distribute surplus capital through dividends and buybacks.
-
Group collaboration. Examples: collaboration between Momentum Health and Momentum Corporate added 30,000 members, and vertical integration of tied advice raised net flows into Momentum solutions.
Medium-term financial targets (F2027 ambitions, published 23 July 2024)
| Target | F2027 ambition | FY2025 actual | FY2026 actual | Status |
|---|---|---|---|---|
| Normalised headline earnings | R7bn | R6.26bn | R7.06bn | Achieved a year early |
| Return on equity | 20% | 21.2% | 21.7% | Achieved |
| VNB margin | 1%–2% | 0.6% | 0.5% | Not achieved; the company calls VNB its main concern |
| Dividend payout | 40%–60% of NHE (revised Sept 2025, target midpoint 50%) | 44% of 2H NHE | 43% | Within range, at the lower end |
The group expects to disclose its next strategic plan, covering the period to FY2030, within the next 12 months (FY2026 results, per Moonstone).
Strategic initiatives in the last 24 months (October 2024 – October 2026)
| Initiative | Date | Description | Targets / outcome |
|---|---|---|---|
| Group performance optimisation programme | FY2025–FY2026 | Group-wide cost and productivity programme | R810m annualised savings by FY2026 year-end; direct expense growth held to 3% |
| Metropolitan Life channel optimisation and turnaround | FY2024–FY2026 | Smaller, more productive agency force; focus on new business quality; system migration | VNB from −R13m to +R60m; margin from −0.2% to 1.1%; NHE R1.15bn |
| Momentum Insure underwriting and claims-procurement optimisation | FY2025–FY2026 | Claims procurement cost optimisation, lead quality, broker tooling (Control) | Combined ratio from 90% to 88% |
| Bonitas administration contract | Awarded Jan 2026; live 1 Jun 2026 | Largest medical scheme administrator transfer in South Africa | Administration market share from 22% to 30% |
| GEMS contract extension | Reported Mar 2026 | Five-year extension of the main administrator contract | Secures the largest health administration client |
| Africa operating model review | Completed FY2025; changes effective FY2026 | Restructured Africa operating model; exits from Ghana and the Mozambique entity | Africa NHE R387m, Botswana and Lesotho turnarounds |
| Capital management | FY2025–FY2026 | R2bn buybacks to Sept 2025; further R1bn completed April 2026; R1.5bn subordinated debt May 2026 | Shares bought at discounts to EV |
| Revised dividend policy | Sept 2025 | Payout range raised from 33–50% to 40–60% of NHE; FY2026 specifies a 50% target | DPS +40% (FY2025), +31% (FY2026) |
| AI and automation | FY2026 | Seven AI use cases generated R40m savings (H1 FY2026); plan to deepen AI use in FY2027 | Ongoing |
| Product relaunches to reduce onerous contracts | FY2025–FY2026 | Repricing and relaunching products that were onerous at inception | Onerous contracts down 39% from R570m to R349m |
| Guardrisk bolt-ons | Dates not disclosed | Acquisitions of Zestlife and Admed (gap cover) | Guardrisk NHE above R1bn |
| Verso acquisition | Effective 1 Sep 2026 | Retirement fund administration and consulting | Scale in Corporate administration |
| Sustainability | F2024 onward | 23% absolute emissions reduction by 2030 vs 2019 (Scope 1, 2, operational Scope 3); CDP B (2025) | See Section 20 |
Products & Services
Product-level specifications, launch years and pricing are generally not disclosed by South African insurers in financial filings.
Momentum Retail (Momentum Life / Momentum Advice and Distribution)
| Offering | Description | Target customer | Launch / latest version | Pricing model |
|---|---|---|---|---|
| Momentum protection (risk) range | Individual life, disability, critical illness and income protection cover. Long-dated protection cash flows make this book sensitive to the ultimate spot-rate assumption (a R320m negative market variance in FY2026 after the assumption was cut from 10% to 9.3%). | Middle and affluent individuals | — | Risk premiums; underwriting-based |
| Investo (long-term savings) | Long-term savings product; FY2026 enhancements drove VNB growth | Middle and affluent savers | Enhanced in FY2026 | Asset-based and policy fees (not disclosed) |
| Momentum Multiply | Rewards and wellness programme linked to Momentum products | Momentum policyholders | — | Programme fees not disclosed; the group's capital-deployment slide references Multiply capital use |
| Momentum Financial Planning (MFP) | Tied advice force | Retail clients | Ongoing | Commission/fee |
| Consult by Momentum | Independent adviser network; AUA up 25% to R59bn (H1 FY2026) | IFAs | Ongoing | Network/support fees not disclosed |
| Momentum Distribution Services (MDS) | Broker distribution | Brokers | Ongoing | — |
| Momentum Money | Transactional/money proposition; appears as a capital consumer in the CMD capital-deployment slide | Retail | — | — |
Momentum Investments
| Offering | Description | Target customer | Launch / latest version | Pricing model |
|---|---|---|---|---|
| Momentum Wealth (local platform) | Linked investment service provider (LISP) platform; Wealth new business +24% in FY2026 | Retail investors via advisers | — | Asset-based platform fees |
| Momentum Wealth International | Offshore platform (products domiciled including Guernsey) | Offshore investors | — | Asset-based fees |
| Guaranteed life annuities | Annuities with guaranteed income for life; volumes −26% in FY2026 | Retirees | Ongoing | Priced on yields and mortality |
| Living annuities | Market-linked drawdown annuities; volumes +14% in FY2026 | Retirees | Ongoing | Asset-based fees |
| Back-to-back products | Structured products repriced in FY2026 | Retail / institutional | — | — |
| Momentum Asset Management | Single-manager asset management | Institutional / retail | Ongoing | AUM fees |
| Momentum Outcome-based Solutions; Momentum Multi-Manager; Momentum Investment Consulting; Momentum Collective Investments; Momentum Alternative Investments | Multi-management, consulting, CIS and alternatives businesses (listed in the 2023 Stewardship Report as discretionary AUM components) | Institutional / retail | Ongoing | AUM fees |
| Momentum Global Investment Management (MGIM) | UK multi-asset manager; acquired Seneca IM (2020) and Crown Agents IM (2023) | UK advisers, DFMs, institutions, international clients | Ongoing | AUM fees |
| Momentum Securities | Securities/stockbroking business, noted for growth in the 2026 strategy update | Retail investors | — | Brokerage fees |
| Student Accommodation Impact Investment Fund | Impact fund that added over 5,000 student beds (2024 Stewardship Report) | Institutional | — | — |
Metropolitan Life
| Offering | Description | Target customer | Launch / latest version | Pricing model |
|---|---|---|---|---|
| Funeral cover | Individual and family funeral plans | Lower- and middle-income households | Ongoing | Monthly premiums |
| Protection (life cover) | Mass-market life cover; products relaunched to reduce onerous contracts | Mass market | Relaunches in FY2025–FY2026 | Monthly premiums |
| Savings and investment plans | Long-term savings products | Mass market | Ongoing | Premium/fee based |
| Annuities | Life annuity products | Retirees in the mass market | Ongoing | Yield/mortality pricing |
| Distribution | Tied agency (reduced 42% FY2024–FY2026), telesales, brokers; adviser productivity up from 2.8 to 3.7 policies a week | — | — | — |
Momentum Corporate
| Offering | Description | Target customer | Launch / latest version | Pricing model |
|---|---|---|---|---|
| FundsAtWork | Umbrella retirement fund (savings and protection components); described as one of the market's largest | Employers (SME to large) | Ongoing | Administration and asset fees |
| Group risk | Employer-paid life, disability and funeral cover | Employers | Ongoing | Group risk premiums |
| Structured investments; single-premium institutional deals | Large single-premium investment mandates | Retirement funds and institutions | Ongoing | Fees/spreads |
| With-profit and guaranteed annuities | Institutional annuity business (main CSM driver in Corporate) | Retirement funds | Ongoing | Yield/mortality pricing |
| Continuation assurance | In-force portfolio; heavier mortality hurt FY2026 | Former group members | In-force | Premiums |
| Verso (from 1 Sep 2026) | Retirement fund administration, benefits consulting, healthcare broking, wealth management, trustee services | Employers and funds | Acquired 2026 | Fees |
Momentum Health
| Offering | Description | Target customer | Launch / latest version | Pricing model |
|---|---|---|---|---|
| Medical scheme administration: GEMS | Main administrator of the Government Employees Medical Scheme; contract extended for another five years (reported March 2026) | Public-sector employees | Extension reported 2026 | Administration and managed-care fees |
| Medical scheme administration: Bonitas | Full administration services from 1 Jun 2026 (managed care went to PHA); adds over 750,000 beneficiaries; more than 600 staff; 17 dedicated service centres | Bonitas members | Go-live 1 Jun 2026 | Administration fees |
| Momentum Medical Scheme administration | Administration of the group-aligned open scheme | Members | Ongoing | Fees |
| Health4Me | Affordable health product with continued growth | Lower-income employees | — | Monthly premiums |
| Capitation contracts | Risk-sharing contracts; favourable claims experience in FY2026 | Schemes / employers | Ongoing | Capitation fees |
Guardrisk
| Offering | Description | Target customer | Launch / latest version | Pricing model |
|---|---|---|---|---|
| First-party cell captives | Corporates self-insure through ring-fenced cells | Large corporates | Ongoing | Management fees plus share of underwriting |
| Third-party (affinity) cell captives | Retailers, banks and brands distribute insurance under cells (Capitec's credit life book moved out in 2024) | Distribution partners | Ongoing | Fees |
| Guardrisk General Insurance (GGI) | Conventional corporate and commercial insurer (including the Inniu property underwriting team); FY2026 underwriting result +26% to R828m | Corporate/commercial | Ongoing | Premiums |
| Guardrisk Life | Life cells and underwriting; FY2026 underwriting result rose from R45m to R244m | Partners | Ongoing | Premiums/fees |
| Admed gap cover | Medical gap cover sold through accredited advisers; 2026 retail family premiums R620/month (Supreme) and R500/month (Primary) | Medical scheme members | 2026 version | Monthly premiums (published) |
| Zestlife | Gap cover business acquired by Guardrisk (acquisition date not disclosed in sources reviewed) | Medical scheme members | — | Monthly premiums |
Momentum Insure
| Offering | Description | Target customer | Launch / latest version | Pricing model |
|---|---|---|---|---|
| Personal lines (motor, home, contents) | Short-term cover through advisers and direct channels | Middle/affluent households | Ongoing | Premiums |
| Commercial lines | Small business cover | SMEs | Ongoing | Premiums |
| Control broker platform | Assets of insurtech Control acquired for R28m to improve quotation delivery to independent brokers | Brokers | FY2026 | — |
Momentum Africa
| Country | Status | Lines |
|---|---|---|
| Namibia | Largest contributor (earnings −17% in FY2026) | Life, health, asset management, pensions administration |
| Botswana | Turnaround in FY2026 | Life and related |
| Lesotho | Turnaround in FY2026; corporate protection growth | Life and related |
| Mozambique | Momentum Mozambique Limitada sold 31 Aug 2026; the company says this is not necessarily a full exit | Non-life / related |
| Ghana | Exited 9 Sep 2025 (sale to emPLE Group) | — |
India: Aditya Birla Health Insurance (ABHI, 44.10%)
| Offering | Description | Notes |
|---|---|---|
| Retail and group health insurance | A "health-first" wellness-led health insurer; one of India's standalone health insurers | First positive full-year IFRS 17 contribution to Momentum NHE in FY2026 (R22m) |
| Momentum Services (India) | Group digital and AI capability based in India, cited in the 2026 Impact strategy update as adding value | Location and headcount not disclosed |
Eris Property Group
Property management and development brand. It manages properties including retail centres in the shareholder and policyholder portfolios (2020 integrated report references solar installations at Eris-managed malls).
Financial Narrative
Applicability note
Momentum Group is an insurance group reporting under IFRS 17. "Gross profit", "EBITDA", "capex", "working capital", "current ratio" and "cash conversion cycle" are not meaningful for an insurer and are not disclosed. The group's primary performance measures are normalised headline earnings (NHE), operating profit (NHE excluding investment return on shareholder funds), the contractual service margin (CSM), value of new business (VNB), embedded value (EV) and SAM solvency cover. The tables below follow that architecture. Unavailable cells are blank.
Earnings (5 years)
Sources: FY2022–FY2023 IFRS 4 from FY2023 results SENS (13 Sep 2023) and company media release; FY2023 restated, FY2024 and FY2025 from FY2024 and FY2025 results SENS; FY2026 from FY2026 results via Moonstone, Business Day and Daily Investor.
Per-share data (5 years)
Discrepancy flag: the restated FY2023 NHEPS was shown as 228.0c in the September 2024 trading statement (based on interim restatements) and 235.2c in the final FY2024 results. The 235.2c figure is used here.
Growth rates and CAGR
NHE CAGR, FY2024–FY2026 (IFRS 17 basis): 26.1% (R4,438m to R7,060m).
NHE CAGR, FY2023 restated–FY2026 (IFRS 17 basis): 26.3% (R3,491m to R7,060m).
NHEPS CAGR, FY2023 restated–FY2026: 31.0% (235.2c to 530.0c). Per-share growth exceeds earnings growth because of buybacks.
DPS CAGR, FY2022–FY2026: 23.1% (100c to 230c).
Revenue CAGR: Not computable. Multi-year IFRS 17 insurance revenue was not available in the sources reviewed.
Margins and returns
Notes: - The FY2026 ROEV of 22.3% is from Daily Investor's report of the FY2026 results, which also cites a FY2025 comparative of 17.9%. The company's FY2025 SENS reported ROEV per share of 19.1%. The difference probably reflects total-EV vs per-share bases; both are shown as reported.
-
Payout ratios are derived as DPS ÷ NHEPS using the basis in force for each year (IFRS 4 for FY2022–FY2023). The company reported a 43% payout for FY2026.
-
An "EBITDA margin" or "gross margin" is not applicable to an insurer.
New business
FY2026 PVNBP of R93.8bn is a rounded media figure (+18%). The company noted that PVNBP growth benefited from lower opening discount yields. CSM was R20,989m at 31 March 2026 (Q3 FY2026 operating update); the FY2026 closing CSM was not available in the sources reviewed.
Balance sheet
FY2024 total assets restated per FY2025 AFS. The H1 FY2026 interim showed restated 30 June 2025 comparatives of R803,213m total assets and R770,259m total liabilities.
FY2026 year-end EV per share and solvency cover were not available in the sources reviewed. Interim data points:
EV per share R44.55 at 31 December 2025: - MML solvency cover 1.76x at 30 September 2025, 1.64x at 31 December 2025 and 1.81x at 31 March 2026, against a target range of 1.6–2.0x.
The group target range is 1.35–1.65x: Debt and other items
Total debt: Third-party data (Simply Wall St, based on FY2025 statements) shows total debt of R10.2bn, a debt-to-equity ratio of 30.9% (down from 50% five years earlier) and interest coverage of 6.5x. The company's own definition and breakdown of borrowings (subordinated debt vs other) were not available in the sources reviewed. A further R1.5bn of subordinated debt was raised on 19 May 2026.
- Short/long split, net debt, goodwill and intangibles, working capital: Not available in the sources reviewed. "Cash and short-term investments" of R747.5bn in third-party data reflects policyholder assets and is not a meaningful liquidity measure for an insurer.
Cash flow and capital returns
Buyback detail: - FY2023: R500m (27.9m shares at an average R17.87, a 43% discount to EV), completed 31 May 2023.
-
FY2024 to early FY2026: R2bn of programmes completed by 12 September 2025. These were the R1bn announced at FY2024 results and the R1bn announced at FY2025 interim results. The second R1bn bought 29.1m shares at an average R34.42 (19% discount to EV of R42.51).
-
FY2026: 45m shares for R1.6bn in total during the financial year. This includes the R1bn programme of 27.4m shares at an average R36.45, completed 8 April 2026.
-
Operating cash flow, capex and free cash flow are not disclosed in a comparable form for an insurer. The group reports "cash earnings" and dividend inflows from subsidiaries. The CMD finance presentation shows cumulative dividend inflows to Momentum Group of R12.6bn over F2022–F2024 as reported on that slide.
Ratios
ROIC, current ratio, net debt/EBITDA, asset turnover and cash conversion cycle are not meaningful for an insurer and are not disclosed.
Commentary on trends, inflections and drivers
FY2022–FY2023: post-Covid recovery under IFRS 4.
-
FY2023 IFRS 4 NHE reached a then-record R5.1bn, helped by fading Covid mortality and favourable yield-curve-driven investment variances.
-
Management itself guided that the underlying run-rate was closer to R4bn a year.
-
That caution was justified: the IFRS 17 restatement cut FY2023 NHE to R3.49bn.
-
The change mainly reflects the IFRS 17 shift to deferring new business profits into the CSM, rather than recognising them upfront, plus other restatements.
FY2024: reset year.
-
NHE grew 27% to R4.44bn on the new basis.
-
Metropolitan Life struggled with high lapse rates.
-
Momentum Insure lost about R300m on severe weather claims and service and integration problems (FY2024 results call, as summarised by GuruFocus).
-
The Impact strategy and F2027 ambitions were set in July 2024 when ROE was 15.5%.
FY2025: inflection.
-
NHE jumped 41% to R6.26bn and ROE reached 21.2%, already above the 20% F2027 target.
-
Drivers were higher CSM release from a larger CSM balance, strong annuity profits in Momentum Investments, better new business profitability and persistency in Metropolitan Life, favourable mortality and morbidity in Momentum Corporate's group risk book, and a turnaround in Momentum Insure (R192m to R438m).
-
Positive assumption changes and favourable yield-curve shifts also helped, which means part of the earnings came from the market.
-
VNB fell 20% because guaranteed annuity volumes dropped and Corporate's mix shifted away from FundsAtWork.
FY2026: target reached a year early.
-
NHE rose 13% to R7.06bn, and every business unit was profitable for the first time.
-
Quality of earnings improved: operating profit rose 9% while market variances fell 67%.
-
Investment return on shareholder funds rose 40% to about R1.09bn.
-
The R810m annualised performance-optimisation savings held direct expense growth to 3%, below inflation.
-
Momentum Retail (−26%) absorbed a R320m negative market variance from the lower ultimate spot-rate assumption.
-
Momentum Corporate (−12%) saw lower reserve releases and heavier continuation-assurance mortality.
-
Buybacks lifted NHEPS 18% against 13% NHE growth.
-
VNB rose only 5% on 18% higher PVNBP, and the margin compressed to 0.5% against a 1–2% target.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansFinancial Detail
Segment Overview
| Segment | What it contains | Key products/services |
|---|---|---|
Momentum Retail | Individual life and savings for middle and affluent markets | Risk/protection, long-term savings (Investo), Multiply rewards; tied and IFA advice |
Momentum Investments | Investment platforms, asset/multi-management, annuities, UK investment management | Momentum Wealth (local/international), guaranteed and living annuities, MGIM, back-to-back products |
Metropolitan Life | Mass-market life insurance | Funeral, protection, savings, annuities; agency, telesales and broker channels |
Momentum Corporate | Employee benefits and institutional | FundsAtWork umbrella funds, group risk, structured investments, with-profit and guaranteed annuities, continuation assurance; Verso (from Sep 2026) |
Momentum Health | Healthcare administration and managed care | Administration of GEMS, Bonitas (from 1 Jun 2026), Momentum Medical Scheme; Health4Me; capitation contracts |
Guardrisk | Specialist and cell-captive insurance | First- and third-party cell captives, Guardrisk General Insurance, Guardrisk Life, gap cover (Admed, Zestlife) |
Momentum Insure | Personal and commercial short-term insurance | Motor, home and contents, small commercial |
Momentum Africa | Operations outside South Africa in Africa | Namibia (largest), Botswana, Lesotho; Ghana exited Sep 2025; Mozambique entity sold Aug 2026 |
India | 44.10% equity-accounted stake in ABHI | Retail and group health insurance in India |
Shareholders | Group capital, central costs, investment return on shareholder funds | — |
Revenue by Segment
| Segment NHE (ZAR Mn) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Momentum Retail | 1,109 | 1,356 | 1,010 |
Momentum Investments | 533 | 963 | 1,190 |
Metropolitan Life | 595 | 868 | 1,148 |
Momentum Corporate | 1,182 | 1,618 | 1,420 |
Momentum Health | 255 | 295 | 367 |
Guardrisk | 653 | 775 | 1,040 |
Momentum Insure | 192 | 438 | 474 |
Momentum Africa | 376 | 288 | 387 |
India | -274 | -67 | 22 |
Shareholders segment | -183 | -274 | — |
Group NHE | 4,438 | 6,260 | 7,060 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansRevenue by Segment (%)
| Contribution to group NHE (%) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
Momentum Retail | 25.0 | 21.7 | 14.3 |
Momentum Investments | 12.0 | 15.4 | 16.9 |
Metropolitan Life | 13.4 | 13.9 | 16.3 |
Momentum Corporate | 26.6 | 25.8 | 20.1 |
Momentum Health | 5.7 | 4.7 | 5.2 |
Guardrisk | 14.7 | 12.4 | 14.7 |
Momentum Insure | 4.3 | 7.0 | 6.7 |
Momentum Africa | 8.5 | 4.6 | 5.5 |
India | -6.2 | -1.1 | 0.3 |
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansSegment NHE growth (%)
| Segment NHE growth (%) | FY2025 | FY2026 |
|---|---|---|
Momentum Retail | 22 | -26 |
Momentum Investments | 81 | 24 |
Metropolitan Life | 46 | 32 |
Momentum Corporate | 37 | -12 |
Momentum Health | 16 | 15 |
Guardrisk | 19 | 26 |
Momentum Insure | 128 | 8 |
Momentum Africa | -23 | 79 |
Group NHE | 41 | 13 |
Operating profit (ZAR Mn)
| Operating profit (ZAR Mn) | FY2024 | FY2025 |
|---|---|---|
Momentum Retail | 907 | 1,192 |
Momentum Investments | 450 | 897 |
Metropolitan Life | 476 | 760 |
Momentum Corporate | 996 | 1,449 |
Momentum Health | 255 | 295 |
Guardrisk | 668 | 797 |
Momentum Insure | 59 | 291 |
Momentum Africa | -27 | -89 |
India | -275 | -69 |
Shareholders segment | 99 | -42 |
Group operating profit | 3,608 | 5,481 |
Investment return on shareholder funds (ZAR Mn)
| Investment return on shareholder funds (ZAR Mn) | FY2024 | FY2025 |
|---|---|---|
Momentum Retail | 202 | 164 |
Momentum Investments | 83 | 66 |
Metropolitan Life | 119 | 108 |
Momentum Corporate | 186 | 169 |
Guardrisk | -15 | -22 |
Momentum Insure | 133 | 147 |
Momentum Africa | 403 | 377 |
India | 1 | 2 |
Shareholders segment | -282 | -232 |
Group investment return | 830 | 779 |
Segment Revenue
| Segment | Indicator | FY2025 | FY2026 |
|---|---|---|---|
Momentum Insure | Claims ratio (%) | 51 | 47 |
Momentum Insure | Expense ratio (%) | 39 | 41 |
Momentum Insure | Combined ratio (%) | 90 | 88 |
Momentum Corporate | Target underwriting margin (net of tax) | 5–7% (company target; UK roadshow) | — |
Metropolitan Life | New business margin (%) | -0.2 | 1.1 |
Momentum Retail | New business margin (%) | 0.5 | 1.0 |
Momentum Investments | New business margin (%) | 1.0 | 0.6 |
Momentum Africa | New business margin (%) | -0.6 | -0.3 |
“—” = not publicly disclosed.
Earnings metric
| Earnings metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
NHE IFRS 4 basis (ZAR Mn) | 4,383 | 5,079 | — | — | — |
NHE IFRS 17 basis (ZAR Mn) | — | 3,491 | 4,438 | 6,260 | 7,060 |
Operating profit IFRS 4 basis (ZAR Mn, approx) | 3,400 | 4,400 | — | — | — |
Operating profit IFRS 17 basis (ZAR Mn) | — | — | 3,608 | 5,481 | 5,970 |
Investment return on shareholder funds (ZAR Mn) | — | — | 830 | 779 | 1,090 |
Earnings attributable IFRS 17 basis (ZAR Mn) | — | — | 3,847 | 5,978 | 6,810 |
Headline earnings IFRS 17 basis (ZAR Mn) | — | — | 4,061 | 6,002 | — |
Insurance revenue (ZAR Mn) | — | — | — | — | 61,400 |
Net insurance and investment result (ZAR Mn) | — | — | — | — | 18,330 |
Per-share metric (ZAR cents)
| Per-share metric (ZAR cents) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
NHEPS IFRS 4 basis | 287.2 | 342.3 | — | — | — |
NHEPS IFRS 17 basis | — | 235.2 | 309.7 | 451.0 | 530.0 |
HEPS IFRS 4 basis | 297.3 | 310.7 | — | — | — |
HEPS IFRS 17 basis (basic) | — | 215.5 | 298.6 | 446.9 | 528.7 |
Diluted HEPS IFRS 17 basis | — | 212.0 | 291.3 | 437.1 | — |
EPS IFRS 4 basis | 260.6 | 313.3 | — | — | — |
EPS IFRS 17 basis (basic) | — | 220.0 | 282.9 | 445.1 | 516.2 |
Diluted EPS IFRS 17 basis | — | — | 276.0 | 435.4 | — |
Dividend per share | 100 | 120 | 125 | 175 | 230 |
Growth metric (%)
| Growth metric (%) | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|
NHE growth (FY2023 on IFRS 4; later years IFRS 17) | 16 | 27 | 41 | 13 |
NHEPS growth (FY2023 on IFRS 4; later years IFRS 17) | 19 | 32 | 46 | 18 |
DPS growth | 20 | 4 | 40 | 31 |
Return / margin metric (%)
| Return / margin metric (%) | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Return on equity (NHE ÷ opening adjusted NAV) | — | — | 15.5 | 21.2 | 21.7 |
Return on embedded value per share | — | — | 13.3 | 19.1 | 22.3 |
VNB margin (VNB ÷ PVNBP) | — | — | 0.7 | 0.6 | 0.5 |
Operating profit ÷ NHE (quality of earnings proxy) | — | — | 81.3 | 87.6 | 84.6 |
Dividend payout of NHEPS (full year, derived) | 34.8 | 35.1 | 40.4 | 38.8 | 43.4 |
Key Financials
| New business metric | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
PVNBP (ZAR Mn) | 82,141 | 79,793 | 93,800 |
VNB (ZAR Mn) | 589 | 469 | 491 |
Recurring premiums (ZAR Mn) | 4,150 | 4,190 | — |
Single premiums (ZAR Mn) | 62,865 | 60,139 | — |
New business CSM (ZAR Mn) | 1,606 | 1,322 | — |
Closing CSM (ZAR Mn) | 19,398 | 20,435 | — |
Onerous contracts value (ZAR Mn) | — | 570 | 349 |
Balance Sheet
| Balance sheet metric (ZAR Mn) | FY2024 | FY2025 | H1 FY2026 (31 Dec 2025) |
|---|---|---|---|
Total assets | 706,575 | 802,823 | 882,707 |
Total liabilities | 676,518 | 769,869 | 848,828 |
Total equity | 30,057 | 32,954 | 33,879 |
Per-Share Data and Financial Ratios (x)
| Other balance sheet / capital metric | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|
Diluted embedded value per share (ZAR) | — | 33.75 | 36.94 | 42.51 |
MML SAM solvency cover (times SCR, pre-foreseeable dividend) | 2.03 | 2.07 | 2.10 | 1.96 |
Momentum Group SAM solvency cover (times SCR) | — | — | 1.65 | 1.58 |
Capital return metric
| Capital return metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Dividend per share (ZAR cents) | 100 | 120 | 125 | 175 | 230 |
Share buybacks executed in year (ZAR Mn) | — | 500 | — | — | 1,600 |
Shares repurchased in year (millions) | — | 27.9 | — | — | 45 |
Margin Analysis (%) and Financial Ratios (x)
| Ratio | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
ROE (%) | 15.5 | 21.2 | 21.7 |
ROA (NHE ÷ total assets, %, derived) | 0.63 | 0.78 | — |
Equity ÷ total assets (%, derived) | 4.25 | 4.10 | — |
Debt ÷ equity (%, third-party) | — | 30.9 | — |
Interest coverage (times, third-party) | — | 6.5 | — |
Revenue by Region
| NHE by geography (ZAR Mn, derived) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
South Africa and UK (all segments except Africa and India, incl. Shareholders) | 4,336 | 6,039 | 6,651 |
Rest of Africa (Momentum Africa segment) | 376 | 288 | 387 |
India (ABHI associate) | -274 | -67 | 22 |
Group NHE | 4,438 | 6,260 | 7,060 |
Share of group NHE by geography (%, derived)
| Share of group NHE by geography (%, derived) | FY2024 | FY2025 | FY2026 |
|---|---|---|---|
South Africa and UK | 97.7 | 96.5 | 94.2 |
Rest of Africa | 8.5 | 4.6 | 5.5 |
India | -6.2 | -1.1 | 0.3 |
PVNBP growth by segment (%)
| PVNBP growth by segment (%) | FY2026 |
|---|---|
Momentum Retail | 8 |
Momentum Investments | 16 |
Metropolitan Life | -14 |
Momentum Corporate | 38 |
Momentum Africa | 45 |
Group | 18 |
VNB by segment (ZAR Mn) | FY2025 |
Momentum Retail | 45 |
Momentum Investments | 509 |
Metropolitan Life | -13 |
Momentum Corporate | -51 |
Momentum Africa | -21 |
Group VNB | 469 |
PVNBP by segment (ZAR Mn) | FY2026 |
Momentum Retail | 9,400 |
Momentum Investments | 57,400 |
Metropolitan Life | 5,600 |
Momentum Corporate | 16,200 |
Momentum Africa | 5,200 |
Group | 93,800 |
JSE MTM share price (ZAR)
| JSE MTM share price (ZAR) | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 |
|---|---|---|---|---|---|
Financial period-end share price | 19.50 | 14.26 | 18.06 | 22.90 | 34.29 |
Price-return metric
| Price-return metric | Value |
|---|---|
Recent price (11 Oct 2026, third-party) | About R36.90 |
52-week range (third-party) | About R32.88 – R42.90 |
Return since 30 Jun 2025 (about 15 months, approx.) | About +7.6% |
1-year return (Fintel, as at 21 Aug 2026) | +11.4% |
3-year return (from 30 Jun 2023, approx.) | About +104% |
5-year return (from 30 Jun 2021, approx.) | About +89% |
Valuation Multiples
| Multiple | Momentum Group | Basis |
|---|---|---|
P/E (NHEPS) | About 7.0x | 530c FY2026 NHEPS |
P/E (HEPS) | About 7.0x | 528.7c FY2026 HEPS |
Price / embedded value | About 0.83x | — |
Price / NAV (book) | About 1.4–1.5x | Sharedata snapshots (2026) |
Dividend yield | About 6.2% | 230c FY2026 DPS |
EV/EBITDA, EV/Sales | Not meaningful for an insurer | — |
Source Details
| Source | Indicator | Value |
|---|---|---|
Fintel (Aug 2026) | Average 1-year price target | R45.62 |
Simply Wall St (Sep 2026) | Analyst consensus target | R44.09 |
TradingView | Target range | R35.85 – R45.26 |
Coverage | Analysts covering | About 10–12 |
Dividend metric
| Dividend metric | FY2022 | FY2023 | FY2024 | FY2025 | FY2026 |
|---|---|---|---|---|---|
Interim DPS (ZAR cents) | — | 50 | — | 85 | 110 |
Final DPS (ZAR cents) | — | 70 | — | 90 | 120 |
Total DPS (ZAR cents) | 100 | 120 | 125 | 175 | 230 |
Capital Programmes
| Programme | Size | Execution |
|---|---|---|
FY2023 interim programme | R500m | 27.9m shares at R17.87 (43% discount to EV); completed 31 May 2023 |
FY2023 results programme | R500m | — |
FY2024 results programme | R1bn | Completed (part of R2bn by 12 Sep 2025) |
FY2025 interim programme | R1bn | 29.1m shares at R34.42 (19% discount to EV) |
FY2025 results programme | R1bn | 27.4m shares at R36.45; completed 8 Apr 2026 |
New programme after FY2026 | Not announced in the sources reviewed | — |
Credit Ratings
| Agency | Entity | Rating | Outlook |
|---|---|---|---|
Moody's | Momentum Metropolitan Life Ltd | Insurance financial strength Ba1 (global); Aaa.za (national) | Linked to sovereign (South Africa Ba2). |
Moody's (Dec 2020) | MML | Long-term issuer Ba2; subordinated debt Ba3(hyb) | Negative at that time (later stable per April 2022 opinion) |
Fitch | Momentum / Metropolitan (historic) | AA(zaf) national IFS (circa 2012) | — |
Analyst Conclusions
Management guidance
-
The F2027 ambitions are NHE of R7bn, ROE of 20% and a VNB margin of 1–2%. The first two have been met a year early; VNB is still short.
-
For FY2027, management expects the operating environment to remain difficult. It will sharpen its focus on VNB and on growing volumes and market share in profitable products, and it will deepen its use of AI and automation (FY2026 outlook, per Business Day).
-
It expects modest South African growth and continued affordability pressure. Lower inflation and falling rates should be a gradual tailwind.
-
A new strategy to FY2030 is due within 12 months.
-
The dividend policy targets a 50% payout of NHE within a 40–60% range.
Consensus growth expectations
-
Consensus earnings forecasts were not available in the sources reviewed.
-
Price targets of about R44–R46 imply roughly 20–24% upside from about R36.90.
-
Simply Wall St's community model references revenue growth of about 3.65% a year.
Bull case
-
Compounding at a discount. At about 7x earnings and about 0.7–0.8x EV, with a 21.7% ROE and a 6%+ yield, continued buybacks below EV (R388m value uplift in FY2026) mechanically compound NHEPS ahead of NHE: +18% NHEPS vs +13% NHE in FY2026.
-
Better earnings quality. Market variances fell 67% while operating profit rose 9%. Five units are each above R1bn, and the CSM is growing toward R21bn, which supports durable release.
-
Health and non-life optionality. Bonitas and the GEMS extension give administration scale. Guardrisk earned R1.04bn and ABHI has turned profitable. These are growth engines outside the commoditised life market.
Bear case
-
VNB is the real test. A 0.5% margin and VNB growth of only 5% on 18% more PVNBP suggest that new business is barely replacing value. The guaranteed-to-living annuity shift is structural, not cyclical, and Momentum Investments' VNB fell 30%.
-
Earnings flattered by benign experience. FY2025–FY2026 benefited from positive assumption changes, a data-reserve release at Metropolitan, favourable mortality and low weather losses. A reversal (as in Corporate's mortality and Retail's yield variance in FY2026) could stall NHE growth near R7bn.
-
Concentration and execution risk. Health administration now depends heavily on two very large schemes. The Bonitas go-live showed service strain and litigation noise, and a contract dispute or service failure could hurt earnings and reputation. Sovereign-capped ratings remain a structural ceiling.
Key catalysts and monitorables (next 12 months)
| Catalyst / monitorable | Expected timing | Why it matters |
|---|---|---|
| FY2026 AGM and any new buyback authorisation | About Nov 2026 | Capital return trajectory |
| Q1 FY2027 operating update | About Nov 2026 | First read on VNB and Bonitas run-rate |
| H1 FY2027 interim results | About Mar 2027 | VNB margin trend; Bonitas earnings contribution; Verso integration |
| Disclosure of FY2030 strategy and new targets | By about Sep 2027 | Resets the investment case |
| Medscheme/Bonitas litigation and CMS investigation outcome | Uncertain | Contract security |
| Guaranteed annuity volumes vs bond yields | Ongoing | Main VNB driver |
| MML solvency cover vs 1.6–2.0x range | Quarterly | Capacity for distributions |
| ABHI growth and IPO or partner actions | Ongoing | India value crystallisation (no transaction announced) |
| South African sovereign rating actions | Ongoing | Ratings and cost of capital |
Concluding analyst verdict
Momentum Group has delivered one of the clearest turnarounds in South African financial services over the past three years. On a consistent IFRS 17 basis, normalised headline earnings doubled from R3.49bn (FY2023 restated) to R7.06bn (FY2026). ROE moved from the mid-teens to 21.7%, and the dividend more than doubled from 100c (FY2022) to 230c. These gains did not come from one lucky line. Metropolitan Life went from chronic under-performer to R1.15bn of earnings. Momentum Insure went from a FY2024 loss-maker to R474m. Guardrisk passed R1bn. India turned positive. Cost discipline (R810m annualised savings) and steady buybacks below embedded value amplified the per-share outcome.
The market still prices the group at roughly 7x earnings and a discount to embedded value. That signals scepticism about whether the earnings base is sustainable, and the scepticism is partly justified. Value of new business, the purest measure of whether today's sales create tomorrow's profits, sits at a 0.5% margin, half the bottom of management's own target range. It is weighed down by a structural move from guaranteed to living annuities that is affecting the whole industry. Recent results also included supportive one-offs (assumption changes, reserve releases) and benign claims experience. The FY2026 Retail and Corporate declines show how quickly those can reverse.
On balance, Momentum is a high-return, cash-generative, capital-returning insurer whose valuation already reflects its VNB weakness. Its new growth sources are health administration scale, Guardrisk and India. The next 12 months hinge on three things. First, whether the FY2030 strategy credibly addresses new-business profitability. Second, whether Bonitas becomes a scale earnings contributor rather than a service liability. Third, whether buybacks continue at a meaningful discount to EV. If VNB margins move toward 1%, the discount looks too wide. If they do not, earnings likely plateau near R7–7.5bn and the shares remain a yield-and-buyback story rather than a growth re-rating.
Unlock Company Financials
Unlock this company profile to view its financial data.
View Subscription PlansExecutive Leadership
Executive Leadership Team
| Name | Title | Tenure (where verified) | Qualifications | Prior roles (verified) |
|---|---|---|---|---|
Jeanette Marais | Group Chief Executive Officer; executive director | Group CEO since 2023 (GlobalData cites August 2023; predecessor retired late 2023) | BSc (Mathematics and Statistics), PED and MBA (cum laude), IMD Switzerland | Deputy CEO of the group; CEO of Momentum Investments; chair of MGIM board (2020) |
Risto Ketola | Group Finance Director; executive director | Group CFO since June 2017 | BSc, CFA, FIA, FASSA | Investor Relations and Business Performance Executive before 2017 |
Dumo Mbethe | CEO: Momentum Corporate; executive director | — | BCom (Accounting and Information Systems), BCom Hons, CA(SA), AMP (Harvard) | — |
Lourens Botha | CEO: Guardrisk | — | BCompt Hons, CA(SA), Chartered Management Accountant | — |
Lulama Booi | CEO: International | — | BCom (Accounting and Computer Science), BCom Hons, CA(SA) | — |
Ravi Govender | Group Chief Digital and Technology Officer | — | MBChB, MSc Management | — |
Johann le Roux | CEO: Momentum Advice and Distribution | Previously listed as CEO: Momentum Retail | BSc Hons (Mathematical Statistics), MBA, FASSA | CEO Momentum Retail |
Jan Lubbe | Group Chief Risk Officer | — | MCom, MBA, CA(SA) | — |
Njabulo Nyawo | Group Chief People Officer | — | BCom Hons, MBA, CA(SA) | — |
Brand Pretorius | CEO: Momentum Insure | — | BCom Law, Advanced Management and Leadership Programme (Oxford) | — |
Peter Tshiguvho | CEO: Metropolitan Life | — | BA (Psychology), MBA, CFP, AMP (Harvard) | — |
Ferdi van Heerden | CEO: Momentum Investments | — | BSc (Hons) Mathematical Statistics, AMP (INSEAD), Dip Management (Henley), MCSI | CEO of Momentum UK / MGIM (2016–2020) |
Stephen van Niekerk | CEO: Momentum Life | — | BCom (Hons), FIA, FASSA | — |
Hannes Viljoen | CEO: Momentum Health | — | MChD (Public Healthcare), DHA, MBL | — |
Board of Directors
| Director | Role | Committee chairs (current) | Appointed (where verified) | Qualifications |
|---|---|---|---|---|
Tyrone Soondarjee | Independent Chair | Nominations | INED 1 Jun 2023; interim chair 7 Nov 2025; Chair 18 Mar 2026 | BAcc (Hons), PG Dip Auditing, CA(SA). Former CFO of Cell C, chair of Grindrod Bank, Group FD of Sasfin, Director of Finance at Deloitte; non-executive chair of Rentworks Holdings |
Jeanette Marais | Group CEO | — | Executive | As above |
Risto Ketola | Group FD | — | Executive | As above |
Dumo Mbethe | Executive director (CEO Momentum Corporate) | — | — | As above |
Linda de Beer | INED | Audit; Remuneration (from 1 Jun 2026) | — | CA(SA), MCom (Tax), Chartered Director |
Nigel Dunkley | INED | Investments | — | BCompt Hons, CA(SA), AMP (Oxford) |
Seelan Gobalsamy | INED | — | — | BCom (Accountancy and Law), PG Dip Accounting, CA(SA), AMP (Harvard) |
Stephen Jurisich | INED | Actuarial; Fair Practices | — | BSc Hons (Actuarial Science), FASSA, FFA |
Frannie Leautier | INED | (Remuneration chair until 31 May 2026) | 1 Jun 2023 | BSc, MSc, PhD (Engineering); Senior Partner, SouthBridge Group |
Phillip Matlakala | INED | — | 1 Jun 2023 | B Juris, B Proc; former CEO of Metropolitan Retail (retired 2014) |
Hillie Meyer | Non-executive (not independent; former Group CEO) | — | 1 Apr 2024 | BCom (Econometrics), FASSA; Momentum CEO 1996–2005; Group CEO 2018–2023 |
David Park | INED | Risk, Capital and Compliance | — | BSc (Actuarial Science), FASSA |
Sharoda Rapeti | INED | Social, Ethics and Transformation | — | HND Electronic Engineering, MBA |
Kobus Sieberhagen | INED | — | — | BA Hons, Masters and PhD (Clinical Psychology), AMP (Oxford) |
Edwin Splinter | INED | — | — | BSc (Mathematics and Statistics), FASSA |
Gcobisa Tyusha | Group Company Secretary | — | — | BCom; PG Dip Business Management |
Board & Management Changes
| Date | Change | Context |
|---|---|---|
1 Jun 2023 | Leautier, Matlakala and Soondarjee appointed INEDs | Board skills refresh under chair Paul Baloyi |
| 2023 | Jeanette Marais becomes Group CEO | Succeeded Hillie Meyer on his retirement |
1 Apr 2024 | Hillie Meyer appointed non-executive director | Continuity and institutional knowledge |
| 2024 | Dan Moyane presented as non-executive chairman at the FY2024 results (September 2024) | — |
7 Nov 2025 | Paul Baloyi resigns as chair (left the board after the 20 Nov 2025 AGM); Soondarjee interim chair | No reason disclosed in the SENS |
18 Mar 2026 | Soondarjee confirmed Independent Chair | Continuity appointment |
31 May / 1 Jun 2026 | Soondarjee leaves the Audit and SET committees; Leautier steps down as Remuneration chair; Linda de Beer becomes Remuneration chair | Committee rebalancing |
Major Shareholders
| Shareholder | Stake | As at / source |
|---|---|---|
Public Investment Corporation (SOC) Ltd | 15.70% | 30 Oct 2024 (Profile's Stock Exchange Handbook 2025 Issue 3); about 16% per Simply Wall St (April 2025) |
Government Employees Pension Fund | 15.15% | Profile's Handbook 2025 Issue 1. GEPF assets are managed by the PIC, so this likely overlaps with the PIC line and should not be added to it |
Kagiso Tiso Holdings (Pty) Ltd | About 7.9% | — |
M&G Investment Managers (Pty) Ltd | — | Simply Wall St top holders list (Dec 2025) |
The Vanguard Group | — | Same |
Ninety One UK | — | Same |
Sanlam Investment Management | — | Same |
Coronation Fund Managers | — | Simply Wall St (OTC listing view) |
Norges Bank Investment Management | — | Same |
STANLIB Asset Management | — | Same |
Momentum Asset Management / Momentum Multi-Manager (policyholder and client holdings) | — | Same |
“—” = not publicly disclosed.
Competitive Landscape
Competitors by Segment
| Segment | Key competitors |
|---|---|
Individual life and savings (Momentum Retail) | Sanlam (Sanlam Personal Finance), Old Mutual (Mass and Foundation, Personal Finance), Discovery Life and Invest, Liberty (Standard Bank Group), BrightRock, PPS, Assupol (now part of Sanlam), Capitec Life |
Mass-market life and funeral (Metropolitan Life) | Old Mutual Mass and Foundation Cluster, Sanlam (Assupol, Safrican), Clientele, Hollard, Capitec Life, AVBOB, retailer and bank-led funeral offerings |
Platforms, annuities and asset management (Momentum Investments) | Allan Gray, Ninety One, Coronation, Glacier (Sanlam), Old Mutual Wealth, Discovery Invest, PSG/Ninety One platforms, Liberty/STANLIB; annuity writers including Sanlam, Old Mutual, Just Retirement (via partners) |
Employee benefits (Momentum Corporate) | Old Mutual Corporate, Sanlam Corporate, Alexander Forbes, Liberty Corporate, NMG Benefits; the Verso acquisition adds administration capacity |
Healthcare administration (Momentum Health) | Discovery Health (largest administrator), Medscheme (AfroCentric, Sanlam-aligned), Medihelp, other in-house scheme administrators |
Specialist and cell-captive insurance (Guardrisk) | Centriq (Santam), Hollard (cell structures), Old Mutual Insure specialist, Sanlam/Santam specialist |
Personal short-term insurance (Momentum Insure) | OUTsurance, Santam, Discovery Insure, Old Mutual Insure (iWYZE), King Price, Hollard, MiWay (Sanlam) |
India health (ABHI) | Star Health and Allied, Niva Bupa, Care Health, ManipalCigna, multi-line general insurers |
Africa | Sanlam (SanlamAllianz JV), Old Mutual, local insurers in Namibia, Botswana and Lesotho |
Peer Comparison FY2025
| Metric | Momentum Group | Sanlam | Old Mutual | Discovery |
|---|---|---|---|---|
Fiscal year end | 30 Jun 2026 | 31 Dec 2025 | 31 Dec 2025 | 30 Jun 2026 |
Core earnings measure | NHE R7.06bn | Net result from financial services R15.94bn; net operational earnings R17.15bn | Results from operations R9.82bn; adjusted headline earnings R8.26bn | Normalised headline earnings R11.80bn; normalised operating profit R17.75bn |
Core earnings growth | +13% | NRFFS +3% (+20% normalised) | RFO +13%; AHE +24% | NHE +21%; normalised operating profit +17% |
Life VNB | R491m | R2.29bn | Not compiled here | Not compiled here |
VNB margin | 0.5% | 2.01% | 1.2% | Not compiled here |
PVNBP | R93.8bn | R113.9bn (life) | Not compiled here | Not compiled here |
ROE / RoNAV | 21.7% ROE | Not compiled here | 15.2% RoNAV | 15.4% normalised ROE (FY2025) |
Embedded / equity value per share | About R44.55 EV (Dec 2025) | GEV R87.73 | GEV R19.80 | Not compiled here |
Dividend per share (full year) | 230c (+31%) | Not compiled here | 93c (+8%) | 384c (+33%) |
R&D intensity | Not disclosed (not applicable) | — | — | — |
“—” = not publicly disclosed.
Competitive Advantages & Vulnerabilities
| Advantages | Vulnerabilities |
|---|---|
Multi-brand coverage from mass market (Metropolitan) to affluent (Momentum) to corporate | Lowest VNB margin among peers; dependent on guaranteed annuity demand |
Guardrisk's leadership in cell captives, with diversified non-life earnings | Third-party cell partners can in-source (Capitec precedent, 2024) |
Health administration scale (GEMS + Bonitas), about 30% market share | Heavy concentration on two scheme clients; execution risk shown in Bonitas transition problems |
Advice-led distribution (MFP, Consult, MDS, agency) | Agency-cost intensity; Metropolitan's volumes are falling |
Strong capital position (MML SCR inside the 1.6–2.0x range); buyback capacity | Credit ratings capped by the South African sovereign |
Highest ROE among peers | Earnings sensitive to yield-curve assumptions (R320m FY2026 Retail variance) |
Recent Developments
Headcount reductions are implicit in Metropolitan Life's agency optimisation (tied agents −42% over FY2024–FY2026). Momentum Health staffed more than 600 roles for Bonitas.*



